1-3 of 3
Robert B. Clarke
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP

Luke Piggott, Andreia Silva, Timothy Robinson, Angelica Santiago-Gómez, Bruno M. Simões, Michael Becker, Iduna Fichtner, Ladislav Andera, Philippa Young, Christine Morris, Peter Barrett-Lee, Fouad Alchami, Marco Piva, Maria dM. Vivanco, Robert B. Clarke, Julia Gee, Richard Clarkson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (10): 2452–2463.
https://doi.org/10.1158/1078-0432.CCR-17-1381
Published: 14 May 2018
View article titled, Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP
Open the PDF for Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP in another window
Includes: Supplementary data
Journal Articles

Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway

Lana McClements, Anita Yakkundi, Angelos Papaspyropoulos, Hannah Harrison, Matthew P. Ablett, Puthen V. Jithesh, Hayley D. McKeen, Rachel Bennett, Christopher Donley, Adrien Kissenpfennig, Stuart McIntosh, Helen O. McCarthy, Eric O'Neill, Robert B. Clarke, Tracy Robson
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (14): 3881–3893.
https://doi.org/10.1158/1078-0432.CCR-13-0595
Published: 15 July 2013
View article titled, Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
Open the PDF for Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway in another window
Includes: Supplementary data
Journal Articles

Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms

Jagdeep K. Singh, Gillian Farnie, Nigel J. Bundred, Bruno M Simões, Amrita Shergill, Göran Landberg, Sacha J. Howell, Robert B. Clarke
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (3): 643–656.
https://doi.org/10.1158/1078-0432.CCR-12-1063
Published: 31 January 2013
View article titled, Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms
Open the PDF for Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms in another window
Includes: Supplementary data